Thrombotic and bleeding complications in patients with AL amyloidosis

Despina Fotiou,Foteini Theodorakakou,Sotiria Spiliopoulou,Maria Gavriatopoulou,Magdalini Migkou,Nikolaos Kanellias,Evangelos Eleutherakis‐Papaiakovou,Panagiotis Malandrakis,Ioanna Dialoupi,Maria Roussou,Ioannis Ntanasis‐Stathopoulos,Evangelos Terpos,Meletios A. Dimopoulos,Efstathios Kastritis

DOI: https://doi.org/10.1111/bjh.19331

2024-02-08

British Journal of Haematology

Abstract:Haemostatic abnormalities and deregulated coagulation are common complications in AL amyloidosis. A retrospective analysis of clinically significant thrombotic/haemorrhagic events in 450 consecutive patients with AL amyloidosis was performed. Venous thromboembolic events (VTEs) were reported in 6% and arterial embolic events in 5% of patients, respectively, during a 55‐month median follow‐up. Multiple risk factors were identified, but thrombosis was the only independent prognostic variable (HR 9.3, p = 0.001) for VTE. Significant bleeding events were reported in 9%, and associated mortality was 19%. The cumulative probability of thrombosis/bleeding is higher during the first year following diagnosis, but a stable lower risk for both events remains for the duration of follow‐up. Summary Haemostatic abnormalities and deregulated coagulation are common complications in AL amyloidosis. The relevant risks of thromboembolic and haemorrhagic events have not been thoroughly evaluated. To describe clinically significant thrombotic/haemorrhagic events in 450 consecutive patients with AL amyloidosis. Venous thromboembolic events (VTEs) were reported in 6% and arterial embolic events (AEEs) in 5% of patients, respectively, during a 55‐month median follow‐up. Lower albumin, lower eGFR, higher BM infiltration, soft tissue involvement, IMiD‐based therapy and prior thrombosis were associated with VTE risk. Prior thrombosis was the only independent prognostic variable (HR 9.3, p = 0.001). Coronary arterial disease, prior AEE, 24‐h proteinuria and higher platelet counts were associated with AEE risk. Significant bleeding events were reported in 9%, and associated mortality was 19%. Liver involvement, higher serum creatinine and higher baseline VWF:Ag levels were linked to bleeding risk. Using competing risk analysis, the cumulative probability of thrombosis/bleeding was higher during the first year following diagnosis, but a stable lower risk for both events remained for the duration of follow‐up. In AL amyloidosis patients, the risk of thrombotic/arterial embolic events is significant, but the bleeding risk is also high. A multiparametric assessment is required to initiate anti‐thrombotic or anti‐platelet therapy appropriately.

hematology